Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- New trial Spotlight
Multiple myeloma
Phase 1 GC012F Dual CAR T-cell Therapy Targeting CD19 and BCMA for Multiple Myeloma
This phase 1 study is investigating GC012F in early-line treatment for multiple myeloma, including newly diagnosed high-risk and relapsed/refractory cases. The trial uses a single infusion of a dual CAR T-cell…
NCT07073547 First-in-human - New trial Spotlight
Kidney cancer
Phase 1 study of 111In-XYIMSR-01 radiotracer for clear cell renal cell carcinoma detection.
An early-phase open-label study at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins evaluates the safety and tumor-targeting performance of 111In-XYIMSR-01 via SPECT/CT in participants with metastatic clear…
NCT07062549 First-in-human - New trial Spotlight
Sarcoma and GIST
Phase 1 MBRT: tungsten‐slit collimator enables spatially fractionated minibeam radiation therapy
Investigating the safety and optimal dose of MBRT at Mayo Clinic, this study tests minibeam radiation—delivered via a tungsten slit collimator that creates alternating peak and valley dose regions—in patients with…
NCT07062003 First-in-human - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 3 Trial: Bleximenib Menin-MLL Inhibitor for Acute Myeloid Leukemia
This Phase 3 randomized, double-blind study evaluates whether adding investigational bleximenib (a Menin-MLL inhibitor) to venetoclax (BCL2 inhibitor) plus azacitidine (DNA methylation inhibitor) improves outcomes…
NCT06852222 Registrational - New trial Spotlight
Ovarian cancer
Phase 3 trial: IP IMNN-001, a first‐in‐class peritoneal modulator
This randomized, adaptive, open label multicenter study sponsored by Imunon evaluates the safety and efficacy of IP IMNN-001 combined with standard neoadjuvant and adjuvant chemotherapy and maintenance therapy versus…
NCT06915025 Registrational - New trial Spotlight
Pancreatic cancer
Phase 1b Alpha DaRT diffusing alpha radiation emitter for pancreatic cancer
This Phase 1b multi-center study evaluates the safety and early efficacy of combining mFOLFIRINOX chemotherapy with Alpha DaRT—a device that emits targeted alpha particles—administered during the first four treatment…
NCT06698458 First-in-human - Trial result Spotlight
Breast cancer
Biomarker Duo sTILs + TNBC-DX Flags 91% pCR With PD-1/Carbo-Taxane in Early TNBC
Pembrolizumab, a PD-1 antibody, combined with neoadjuvant docetaxel-carboplatin (TCb + Pem) in the Phase II NeoPACT study (NCT03639948, n = 115) for stage I-III triple-negative breast cancer delivered a 58% overall…
NCT03639948 - Trial result Spotlight
Stomach and esophageal cancer
EGFR×HER3 bispecific ADC logs 40% responses in PD‑1‑refractory metastatic ESCC
BL‑B01D1 pairs an EGFR‑HER3 bispecific antibody with a cleavable topoisomerase I payload; in the phase 1b NCT05262491 study, 82 heavily pre‑treated ESCC patients received 2.0 or 2.5 mg/kg every 3 weeks. Overall…
NCT05262491 - New trial Spotlight
Breast cancer
Phase 3 Sac-TMT ADC: TROP2-directed antibody-drug conjugate.
This Phase 3 trial compares sac-TMT (a TROP2-directed antibody-drug conjugate) plus pembrolizumab and chemotherapy to a pembrolizumab-chemotherapy regimen as neoadjuvant treatment. Enrolling patients with high-risk,…
NCT06966700 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase 2 Trial of Raludotatug deruxtecan ADC targeting CDH6
In this randomized umbrella study under a pembrolizumab master protocol, participants with previously treated Stage IV squamous NSCLC receive treatments every 3 weeks until disease progression. Investigational arms…
NCT06780098 Exploratory - New trial Spotlight
Pancreatic cancer
Phase I/IIa Trial of E-EDV-D682 Nanocells Targeting EGFR in Metastatic PDAC
This randomized study compares the efficacy and safety of E-EDV-D682/GC nanocells in combination with gemcitabine (a ribonucleoside reductase inhibitor) and nab-paclitaxel (a tubulin inhibitor) versus standard…
NCT07049055 First-in-human - New trial Spotlight
Melanoma
Phase 2 trial: V940 mRNA cancer vaccine & Pembrolizumab PD-1 inhibitor in advanced melanoma
This Phase 2 study evaluates whether a patient-specific TAA mRNA vaccine (V940) given by IM injection alongside IV pembrolizumab (a PD-1 inhibitor) can prolong progression-free survival compared to placebo plus…
NCT06961006 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1/2a trial of NTS071, a TP53 Y220C directed activator
This Phase 1/2a study by Nutshell Therapeutics (Shanghai) Co., LTD. evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in adults with advanced solid tumors harboring a TP53 Y220C…
NCT07060989 First-in-human - Trial result Spotlight
Ovarian cancer
Avutometinib + Defactinib (RAF-MEK clamp / FAK blocker) Posts 42% ORR and 20 mo PFS in Refractory Low-Grade Serous OC (LGSOC)
In the first-in-human phase 1 FRAME trial (NCT03875820), 26 heavily pre-treated low-grade serous ovarian cancer patients received intermittent avutometinib 3.2 mg once daily (BIW, 3-weeks-on/1-off) plus continuous…
NCT03875820 - Trial result Spotlight
Melanoma
Pembrolizumab + ATRA (MDSC-Targeting) Posts 55% 5-Year OS in Metastatic Melanoma
All-trans retinoic acid (ATRA), a differentiating agent that depletes immunosuppressive myeloid-derived suppressor cells, was pulsed at 150 mg/m² orally on days −1/0/+1 of the first four pembrolizumab 200 mg Q3W…
NCT03200847 - Trial result Spotlight
Acute lymphoblastic leukemia
Fresh CD19 CAR T Achieves 100% MRD-Neg CR, 83% 3-yr OS in r/r Pediatric B-ALL
A point-of-care, second-generation 4-1BB CD19 CAR T product was manufactured fresh in 12 days and infused in the Phase I/II NCT04787263 trial (n = 19) enrolling children/young adults in very-high-risk first relapse…
NCT04787263 - New trial Spotlight
Non-small cell lung cancer
Phase 2 study of Telisotuzumab Vedotin, c‑Met–targeted ADC with tubulin inhibitor, in NSCLC
AbbVie is testing telisotuzumab vedotin—a c‑Met–targeted antibody-drug conjugate with a tubulin inhibitor—in adults with previously treated, c-Met-overexpressing, EGFR-wild-type, advanced non-squamous NSCLC—a…
NCT06568939 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1 trial of MGC028, an ADAM9-directed Topo I inhibitor ADC for advanced solid tumors.
This Phase 1 study led by MacroGenics evaluates safety, tolerability, and optimal dosing of MGC028 in adult patients with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors.…
NCT06723236 First-in-human - New trial Spotlight
Multiple solid tumors
Phase II ADC MATCH: sacituzumab govitecan (Trop‑2 ADC), enfortumab vedotin (nectin‑4 ADC), trastuzumab deruxtecan (HER2 ADC) trial
This Phase II study by the National Cancer Institute uses molecular screening with IHC assays to assign patients with advanced solid tumors lacking standard care options to one of three treatment cohorts. In each…
NCT06311214 Exploratory - Trial result Spotlight
Acute lymphoblastic leukemia
Subcutaneous Blinatumomab Achieves 77% CR in Relapsed/Refractory B-ALL, Surpassing IV Benchmarks
Blinatumomab, a CD19×CD3 bispecific T-cell engager, was reformulated for subcutaneous (SC) delivery and evaluated in the phase 1/2 NCT04521231 study across 88 adults with relapsed/refractory B-cell ALL. Once-daily…
NCT04521231 - New trial Spotlight
Breast cancer
Phase 3 Inavolisib PI3K inhibitor trial in advanced breast cancer
This multicenter study by Hoffmann-La Roche compares inavolisib plus letrozole and a CDK4/6 inhibitor versus placebo with the same backbone in patients with PIK3CA-mutated, hormone receptor–positive, HER2–negative…
NCT06790693 Registrational - New trial Spotlight
Prostate cancer
Phase 3 trial of Mevrometostat, an EZH2 inhibitor, with Enzalutamide in metastatic castration-sensitive prostate cancer
This randomized trial evaluates whether combining investigational Mevrometostat with enzalutamide improves outcomes for ARPI-naïve, chemo-naïve metastatic castration-sensitive prostate cancer patients compared to…
NCT07028853 Registrational - New trial Spotlight
Neuroendocrine and adrenal tumors
Phase Ib/II ZL-1310: DLL3-targeted Topoisomerase I inhibitor in selected solid tumors.
This multi-center, open-label trial from Zai Lab (Shanghai) is assessing ZL-1310 as a single-agent therapy in patients with neuroendocrine carcinomas progressing after platinum therapy. The study is conducted at…
NCT06885281 Exploratory - New trial Spotlight
Multiple myeloma
Phase 2 teclistamab bispecific BCMA/CD3 antibody trial in high-risk multiple myeloma
This open-label Phase 2 trial investigates sequencing of teclistamab, daratumumab, and talquetamab—with or without melphalan transplant—for newly diagnosed high-risk multiple myeloma patients stratified by minimal…
NCT07029776 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1 study of ERAS-0015, a RAS inhibitor small molecule.
This open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of ERAS-0015 administered alone or with additional investigational agents in patients with advanced or metastatic…
NCT06983743 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 TNG462 PRMT5 inhibitor trial with KRAS inhibitor combinations.
This open-label, multicenter trial evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral TNG462 combined with investigational KRAS agents RMC-6236 or RMC-9805…
NCT06922591 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 trial ARV-806 KRAS (G12D) inhibitor in advanced cancer.
This open-label Phase 1/2 study evaluates ARV-806 administered via IV infusion in adults with advanced KRAS G12D-mutated tumors, including metastatic pancreatic ductal adenocarcinoma. Sponsored by Arvinas Inc. and…
NCT07023731 First-in-human - New trial Spotlight
Other blood cancers and transplant
Phase 1 trial of ruxolitinib, a JAK1 inhibitor for preventing GVHD
Investigating biomarker-guided ruxolitinib for preventing chronic GVHD in post-transplant patients, this Phase 1 trial compares ruxolitinib monotherapy starting about 105 days after allogeneic HCT versus…
NCT07025538 Exploratory - Trial result Spotlight
Breast cancer
T-DXd Outscores T-DM1 Across HER2 Copy-Number, PI3K, and HRD Genomic Subsets in DESTINY-Breast03
In this ctDNA biomarker dive from the Phase III DESTINY-Breast03 trial (n≈420), researchers profiled >700 genes at baseline and progression. Despite wide heterogeneity—PIK3CA 48%, TP53 73%, HER2 amplifications…
- Trial result Spotlight
Breast cancer
Gedatolisib (pan-PI3K/mTOR) Triplet Hits 85% ORR in HR+/HER2- mBC
Gedatolisib 180 mg IV weekly plus palbociclib and letrozole/fulvestrant was explored in the phase 1b NCT02684032 dose-expansion (four cohorts by prior therapy). ORR reached 85% with 72% 12-mo PFS in treatment-naïve…
NCT02684032
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.